RARA CRAFT DATABASE for FDA Medical Devices
PMAP190032S010

FDA DEVICE FACTS

FoundationOne Liquid CDx (F1 Liquid CDx)

Foundation Medicine, Inc.

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEJune 8, 2023PRODUCT CODEPQP

Indications for use

FoundationOne Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions, insertions and deletions (indels) in 311 genes, rearrangements in eight (8) genes, and copy number alterations in three (3) genes. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from

plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOne Liquid CDx cfDNA blood collection tubes included in the FoundationOne Liquid CDx Blood Sample Collection Kit. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1: Companion diagnostic indications Tumor Type Biomarker(s) Detected Therapy Non-small cell lung ALK Rearrangements ALECENSA® (alectinib) cancer (NSCLC) EGFR Exon 19 deletions and EGFR Exon 21 L858R substitution EGFR tyrosine kinase inhibitors approved by FDA* EGFR Exon 20 insertions EXKIVITY® (mobocertinib) MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping TABRECTA® (capmatinib) ROS1 fusions** ROZLYTREK® (entrectinib) Prostate cancer BRCA1, BRCA2, and ATM alterations LYNPARZA® (olaparib) BRCA1, BRCA2 alterations RUBRACA® (rucaparib) Breast Cancer PIK3CA mutations C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y PIQRAY® (alpelisib) Solid Tumors NTRK1/2/3 fusions** ROZLYTREK® (entrectinib) Colorectal cancer (CRC) BRAF V600E alteration BRAFTOVI ® (encorafenib) in combination with cetuximab *For the most current information about the therapeutic products in this group, go to: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools#Group_Labeling Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. A negative result from a plasma specimen does not mean that the patient’s tumor is negative for genomic findings. Patients who are negative for the mutations listed in Table 1 (see **Note for NTRK1/2/3 and ROS1 fusions) should be reflexed to routine biopsy and

their tumor mutation status confirmed using an FDA-approved tumor tissue test, if feasible. **Note: when considering eligibility for ROZLYTREK® based on the detection of NTRK1/2/3 and ROS1 fusions, testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing. Genomic findings other than those listed in Table 1 of the intended use statement are not prescriptive or conclusive for labeled use of any specific therapeutic product. FoundationOne Liquid CDx is a single-site assay performed at Foundation Medicine, Inc. in Cambridge, MA.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026